Therapy | Page 162 of 190 | SpiritIndia.com

Breast Cancer :: Risk of anemia reduced by exercise in breast cancer patients

Women undergoing radiation treatment for breast cancer benefit from moderate intensity, regular aerobic activity, according to a new study. Published in the November 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study found that exercise improved the oxygen capacity of patients and maintained levels of red blood cells during radiation treatment. In contrast, women who did not exercise experienced significant declines in their oxygen capacity. This is the first study to investigate the effect of exercise during treatment.

Asthma :: Mutual recognition procedure for Symbicort maintenance n reliever therapy Symbicort smart

AstraZeneca announced that it has successfully completed the European Union Mutual Recognition Procedure (MRP) for Symbicort? Maintenance And Reliever Therapy (Symbicort SMART?). This new asthma treatment approach allows patients to use just one inhaler for both maintenance and relief of asthma symptoms.

Neurology :: What is neuroprotection?

Neuroprotection is the mechanisms and strategies used to protect against neuronal injury or degeneration in the Central Nervous System (CNS) following acute disorders (e.g. stroke or nervous system injury/trauma) or as a result of chronic neurodegenerative diseases (e.g. Parkinson’s, Alzheimer’s, Multiple Sclerosis).

Breast Cancer :: Critical gaps in breast cancer patient education and communication

Results from a recent survey of European women with early breast cancer, presented for the first time at the European Society for Medical Oncology (ESMO) congress, show that the information needs of patients are not being met and that there is an unacceptably low level of patient involvement in potentially life-extending treatment decisions. The survey revealed that older women, those with a low level of education and those without Internet access are particularly uninformed.

Multiple Sclerosis :: Treatment of relapsing-remitting multiple sclerosis

UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II clinical trials next year.

Sleep :: Australasian sleep association, Perth – conference highlights

Snorers Cause Bed Partners to have EEG Arousals (91)Sean Tolhurst, University of Queensland and SNORE Australia – A new study has found that people with sleep apnea cause their bed-partners to have EEG arousals and sleep disturbance. Up until now there has been limited scientific information into how much a patient with Obstructive Sleep Apnea disturbs a sleeping bed partner. This study investigated the impact that snoring and sleep apnea events have on the bed-partner.

Multiple Sclerosis :: Fty720 – fingolimod reduces multiple sclerosis symptoms

The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.

Health :: Antibiotic Ceftobiprole shows promise against MRSA infections

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. today announced that ceftobiprole, a novel cephalosporin(1) antibiotic in Phase III clinical trials, was found to be active against complicated skin infections caused by common, potentially deadly bacteria, including MRSA. These data were from two poster presentations given at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). These data also were highlighted by ICAAC. Ceftobiprole is being co-developed with Basilea Pharmaceutica, Ltd. through an exclusive worldwide collaboration.

Smoking :: Pfizer’s anti-smoking pill Champix approved in europe

Pfizer Inc said today that the European Commission has approved Champix(R) (varenicline), a novel pill for smoking cessation in adults. In addition, because smokers often need considerable support to quit successfully, Champix will be available with a patient support plan which smokers can customize to address their individual behavioral triggers as they try to quit smoking.

Lymphoma :: New indications for rituxan in patients with non-hodgkin’s lymphoma

Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved, after a Priority Review, two additional uses for Rituxan(R) (Rituximab) for patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL). One new indication for Rituxan is for first-line treatment of previously-untreated patients with follicular NHL in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. The second new indication is for the treatment of low-grade NHL in patients with stable disease or who achieve a partial or complete response following first-line treatment with CVP chemotherapy.